NEW YORK--(BUSINESS WIRE)--In a new study, NYU Stern Professor Deepak Hegde and Bhaven Sampat of Columbia University investigate whether lobbying by special interest groups affects funding for research by the National Institutes of Health (NIH), a publicly funded federal agency and the world’s largest funder of medical research – nearly $30 billion each year. They found that lobbying does have an effect on NIH research grants, and showed the subtle mechanism of how lobbyists’ influence plays out.
The authors analyzed lobbying and NIH funding for 955 rare and often fatal diseases – including Parkinson’s Disease, Cystic Fibrosis, Multiple Sclerosis, Sickle Cell Disease, Huntington’s Disease, Hodgkin’s Disease, Cerebral Palsy and Spina Bifida – between 1998 and 2008.
Key findings include:
- Lobbying by disease advocates mobilizes political support in the form of Congressional “soft earmarks” for specific diseases. Soft earmarks refer to language in the reports that accompany Congressional appropriations bills urging the NIH to support research on particular diseases or research fields.
- Lobbying is particularly effective in mobilizing political support when accompanied by scientific advances related to diseases and/or an increase in the number of related mortalities.
- The NIH appears to respond to Congressional earmarks through special grant mechanisms (i.e., “Requests for Applications” and “Program Announcements”), which solicit research proposals in particular areas of research, rather than through grants for unsolicited investigator-initiated research.
- The overall effect of lobbying and earmarks on NIH funding appears to be in the range of 3-15 percent of the agency’s new spending on rare diseases, which amounts to less than one-third of all NIH grants each year.
“The NIH is known for funding research projects based on their scientific merit, but recent critics have alleged that disease advocates influence NIH funding decisions and distort funding toward research on diseases favored by special interest groups,” says Professor Hegde. “Our research shows that the mechanisms for influence are complex, but that lobbying may have a useful, informational role and does impact federal funding for biomedical research. That said, the channels of political influence are subtle, affect only a small portion of funding and may not have a distortive effect on public science.”
The article, “Can Private Money Buy Public Science? Disease Group Lobbying and Federal Funding for Biomedical Research,” is forthcoming in Management Science.
To speak with Professor Hegde, please contact him directly at 212-998-0674 or firstname.lastname@example.org; or contact Carolyn Ritter in NYU Stern’s Office of Public Affairs at 212-998-0624 or email@example.com.